Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
10,500
-140 (-1.32%)
Feb 11, 2026, 5:28 PM IDT
Market Cap122.87B +37.5%
Revenue (ttm)55.02B +4.3%
Net Income4.50B
EPS3.86
Shares Outn/a
PE Ratio27.33
Forward PE12.72
Dividendn/a
Ex-Dividend Daten/a
Volume817,314
Average Volume2,004,069
Open10,650
Previous Close10,640
Day's Range10,500 - 10,800
52-Week Range4,865 - 11,350
Beta0.72
RSI53.99
Earnings DateJan 28, 2026

About TLV:TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 32,842
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Noteworthy ETF Inflows: SPDW, SPOT, SE, TEVA

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) where we have ...

16 hours ago - Nasdaq

TEVA: Goldman Sachs Raises Price Target to $45, Maintains Buy Rating | TEVA Stock News

TEVA: Goldman Sachs Raises Price Target to $45, Maintains Buy Rating | TEVA Stock News

2 days ago - GuruFocus

Teva (TEVA) Q4 2024 Earnings Call Transcript

Teva (TEVA) Q4 2024 Earnings Call Transcript

6 days ago - The Motley Fool

Teva (TEVA) Q3 2024 Earnings Call Transcript

Teva (TEVA) Q3 2024 Earnings Call Transcript

6 days ago - The Motley Fool

A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings

In the current market session, Teva Pharmaceutical Indus Inc. (NYSE: TEVA) stock price is at $34.94, after a 0.33% drop. However, over the past month, the company's stock went up by 7.18% , and in th...

6 days ago - Benzinga

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Down 0% on Feb 5

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Down 0% on Feb 5

6 days ago - GuruFocus

Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight

Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight

8 days ago - GuruFocus

Teva Pharmaceutical Industries Ltd (TEVA) Shares Up 3.39% on Feb 3

Teva Pharmaceutical Industries Ltd (TEVA) Shares Up 3.39% on Feb 3

8 days ago - GuruFocus

Notable ETF Inflow Detected - IDEV, SPOT, SE, TEVA

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI International Developed Markets ETF (Symbol: IDEV) w...

8 days ago - Nasdaq

Q4 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

Q4 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

10 days ago - GuruFocus

Barclays Raises Price Target for TEVA to $38, Maintains Overweight Rating | TEVA Stock News

Barclays Raises Price Target for TEVA to $38, Maintains Overweight Rating | TEVA Stock News

12 days ago - GuruFocus

Teva snaps six straight sessions of gains

13 days ago - Seeking Alpha

Scotiabank Raises TEVA Price Target to $40 | TEVA Stock News

Scotiabank Raises TEVA Price Target to $40 | TEVA Stock News

13 days ago - GuruFocus

Truist Securities Raises Teva Pharmaceutical (TEVA) Price Target to $38.00 | TEVA Stock News

Truist Securities Raises Teva Pharmaceutical (TEVA) Price Target to $38.00 | TEVA Stock News

13 days ago - GuruFocus

Teva CEO Richard Francis sits down with Jim Cramer

Teva President and CEO Richard Francis joins 'Mad Money' host Jim Cramer to talk quarterly results, its growth strategy, changed in FDA development pipeline, and more.

14 days ago - CNBC

Teva (TEVA) Q3 2025 Earnings Call Transcript

Teva (TEVA) Q3 2025 Earnings Call Transcript

14 days ago - The Motley Fool

Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript

Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript

14 days ago - Seeking Alpha

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts' expectations of $4.37 billion, ...

14 days ago - Benzinga

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts' expectations of $4.37 billion,...

14 days ago - Benzinga

Teva Pharmaceutical Industries Limited 2025 Q4 - Results - Earnings Call Presentation

2026-01-28. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2025 Q4 earnings call.

14 days ago - Seeking Alpha

Teva Pharmaceuticals (TEVA) Sets Ambitious FY26 Gross Margin Goals

Teva Pharmaceuticals (TEVA) Sets Ambitious FY26 Gross Margin Goals

14 days ago - GuruFocus

TEVA Targets Fiscal Year 2027 with Ambitious Financial Goals

TEVA Targets Fiscal Year 2027 with Ambitious Financial Goals

14 days ago - GuruFocus

TEVA Targets 2030: Ambitious Profit Goals and Financial Strategies

TEVA Targets 2030: Ambitious Profit Goals and Financial Strategies

14 days ago - GuruFocus

Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for Teva Pharmaceutical Industries (TEVA) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metri...

14 days ago - Nasdaq

TEVA Aims to Double Biosimilar Revenue by 2027

TEVA Aims to Double Biosimilar Revenue by 2027

14 days ago - GuruFocus